June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
The PLGA implant as an antimitotic delivery system after experimental trabeculectomy
Author Affiliations & Notes
  • Ignacio Rodriguez-Agirretxe
    Glaucoma, ICQO, Bilbao, Spain
    Glaucoma, Donostia Hospital, San Sebastian, Spain
  • Sandra Vega
    Bioftalmik SL, Derio, Spain
  • Elena Vecino
    Cellular Biology, University of the Basque Country, Leioa, Spain
  • Javier Mendicute
    Glaucoma, Donostia Hospital, San Sebastian, Spain
  • Fabiola Eder
    Glaucoma, Donostia Hospital, San Sebastian, Spain
  • Tatiana Suarez-Cortes
    Bioftalmik SL, Derio, Spain
  • Arantxa Acera
    Bioftalmik SL, Derio, Spain
  • Footnotes
    Commercial Relationships Ignacio Rodriguez-Agirretxe, None; Sandra Vega, BIOFTALMIK S.L. (E); Elena Vecino, None; Javier Mendicute, None; Fabiola Eder, None; Tatiana Suarez-Cortes, Bioftalmik S.L. (E); Arantxa Acera, BIOFTALMIK SL (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4747. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ignacio Rodriguez-Agirretxe, Sandra Vega, Elena Vecino, Javier Mendicute, Fabiola Eder, Tatiana Suarez-Cortes, Arantxa Acera; The PLGA implant as an antimitotic delivery system after experimental trabeculectomy. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4747.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To investigate the effect of poly (lactic-co-glycolic acid) (PLGA) implants loaded with mitomycin C (MMC) and with different adjuvant treatments after glaucoma filtration surgery (GFS), in comparison to standard treatments.

Methods: Forty-two New Zealand White rabbits underwent bilateral GFS and received different treatments (left eye): topical MMC (group 1); topical 5-fluorouracil (5-FU) (group 2); PLGA implant (group 3); MMC-loaded and -coated PLGA implant (group 4); MMC-loaded and 5-FU-coated PLGA implant (group 5); subconjunctival bevacizumab (group 6); MMC loaded PLGA implant and subconjunctival bevacizumab (group 7) and no treatment (right eye of all animals) (group 8). Intraocular pressure (IOP) and filtering bleb were evaluated at 0, 1, 5, 7, 14, 21 and 28 days after GFS. Histology was performed to examine the conjunctiva, sclerotomy, filtering bleb and persistence of the implant.

Results: The best hypotensive results were achieved in the MMC-loaded and -coated PLGA implant group (group 4), which presented the lowest IOP values on days 1, 5, 7, 14 and 28 after GFS. Excluding the implant groups, bleb survival was superior to controls in groups 1, 2 and lower in group 6. Group 7 presented greater extension, height and vascularization of the bleb. Epithelial thinning and lymphoplasmacytic infiltrate were observed in groups 1, 2, 4, 5 and 7. The rates of closure of the sclerotomy and bleb were 100% and 76% respectively and implant persistence was 95%.

Conclusions: MMC-loaded and -coated implants have optimal surgical results, followed by topical MMC application. In this experimental model, bevacizumab may be antagonistic to MMC.

Keywords: 765 wound healing • 474 conjunctiva  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.